Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-Shiga toxin monoclonal antibodies - Taro Pharmaceuticals

Drug Profile

Anti-Shiga toxin monoclonal antibodies - Taro Pharmaceuticals

Alternative Names: Anti-Stx monoclonal antibodies; c-Stx1; c-Stx1/c-Stx2; c-Stx2; caStx1; caStx1/caStx2; caStx2; Shigamab; Shigamabs

Latest Information Update: 22 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sunol Molecular Corporation; Uniformed Services University of the Health Sciences
  • Developer BELLUS Health; Taro Pharmaceuticals Inc
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Escherichia coli infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Haemolytic uraemic syndrome; Shiga-toxigenic Escherichia coli infections

Most Recent Events

  • 22 Feb 2023 Discontinued - Preclinical for Haemolytic uraemic syndrome in USA (IV) (Taro Pharmaceuticals pipeline, February 2023)
  • 28 Jun 2018 No recent reports of development identified for preclinical development in Haemolytic-uraemic-syndrome in USA (IV, Infusion)
  • 16 Mar 2017 Thallion Pharmaceuticals including anti-Shiga toxin monoclonal antibodies acquired by Taro Pharmaceuticals from Bellus Health
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top